2-Chloro-deoxyadenosine Induces Durable Complete Remission in Castleman's Disease but may Accelerate its Transformation to Non-Hodgkin's Lymphoma

A prospective pilot study of 23 patients with non-Hodgkin's lymphoma involving the stomach was undertaken to assess the efficacy of surgical resection followed by chemotherapy with adjuvant cyclical cyclophosphamide, vincristine, and prednisolone (CVP) in early stage disease, and cyclical cyclophosphamide, vincristine, prednisolone, and doxorubicin (CHOP) in advanced disease. One of 18 evaluable patients died postoperatively; 17 of 18 completed therapy and are alive and disease-free at a median follow-up of 41 months after surgery (range, 5 to 111 months), including four patients with stage IV disease who remain in complete remission 19 to 47 months after surgery. There was one postoperative death, giving an actuarial survival rate of 94% in the study group. Three of five inoperable patients were treated with CHOP, with two achieving complete remission. Two untreated patients died. Overall actuarial disease-free survival was 82.6%. Surgical resection plus chemotherapy is capable of producing long-term remission and cure in both localized and advanced non-Hodgkin's lymphoma of the stomach. Intensive supportive care plus chemotherapy may salvage a proportion of patients with inoperable tumors.

Download Full-text

Non-Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy

Cancer ◽

10.1002/1097-0142(197502)35:2<354::aid-cncr2820350209>3.0.co;2-2 ◽

1975 ◽

Vol 35 (2) ◽

pp. 354-357 ◽

Cited By ~ 31

Author(s):

Philip S. Schein ◽

Bruce A. Chabner ◽

George P. Canellos ◽

Robert C. Young ◽

Vincent T. Devita

Keyword(s):

Complete Remission ◽

Combination Chemotherapy ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine

Blood ◽

10.1182/blood.v66.5.1110.bloodjournal6651110 ◽

1985 ◽

Vol 66 (5) ◽

pp. 1110-1114

Author(s):

GV Dahl ◽

G Rivera ◽

CH Pui ◽

J Jr Mirro ◽

J Ochs ◽

...

Keyword(s):

Complete Remission ◽

Hodgkin’S Lymphoma ◽

Lymphoblastic Leukemia ◽

Alkylating Agents ◽

Central Nervous System Involvement ◽

Hodgkin's Lymphoma ◽

High Dose ◽

Early Therapy ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

We treated 24 children and adolescents with stage III or IV lymphoblastic non-Hodgkin's lymphoma, using a protocol designed for patients with poor-prognosis acute lymphoblastic leukemia (ALL). Early therapy consisted of teniposide plus cytarabine administered before and immediately after prednisone, vincristine, and asparaginase. The two- drug combination was also given intermittently with continuous 6- mercaptopurine and methotrexate during the first year of continuation chemotherapy. Periodic intrathecal methotrexate and delayed cranial irradiation were used to prevent central nervous system involvement. Anthracycline compounds, alkylating agents, high-dose methotrexate, and involved-field irradiation were not used in any phase of treatment. Twenty-two (96%) of the 23 evaluable patients achieved complete remission. With a median follow-up of 2 1/2 years, only four patients have relapsed; the remainder have been disease-free for eight months to more than five years. The projected four-year continuous complete remission rate is 73% for all patients and 79% for the 19 with mediastinal involvement at diagnosis. These results demonstrate that use of teniposide plus cytarabine with an otherwise conventional plan of ALL therapy is an effective approach to the treatment of childhood lymphoblastic lymphoma.

Download Full-text

Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins

Blood ◽

10.1182/blood.v58.3.509.509 ◽

1981 ◽

Vol 58 (3) ◽

pp. 509-513 ◽

Cited By ~ 53

Author(s):

FR Appelbaum ◽

A Fefer ◽

MA Cheever ◽

CD Buckner ◽

PD Greenberg ◽

...

Keyword(s):

Complete Remission ◽

Marrow Transplantation ◽

Hodgkin’S Lymphoma ◽

High Dose Chemotherapy ◽

Marrow Transplant ◽

Hodgkin's Lymphoma ◽

High Dose ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Well Differentiated

Abstract Eight patients with disseminated non-Hodgkin's lymphoma who failed conventional combination chemotherapy were treated with high-dose chemotherapy, a supralethal dose of total-body irradiation, and a bone marrow transplant from a normal identical twin. Seven patients experienced complete remission. Four of the seven patients (two with diffuse poorly differentiated lymphocytic lymphoma, one with composite lymphoma, and one with diffuse moderately well differentiated lymphocytic lymphoma) remain in complete unmaintained remission 12–126 mo from transplantation. One patient relapsed after 10 mo but was retreated and is alive in unmaintained complete remission 73 mo from transplantation. One patient died of Pseudomonas pneumonia while in complete remission and one patient relapsed and died of progressive lymphoma. These results demonstrate that intensive chemoradiotherapy and twin marrow transplantation can induce frequent and enduring remissions in patients with disseminated non-Hodgkin's lymphoma who have failed conventional therapy.

Download Full-text

Systematic Restaging in Non-Hodgkin’s Lymphoma: The Need to Define Complete Remission

Lymphoid Neoplasias II - Recent Results in Cancer Research ◽

10.1007/978-3-642-81249-1_11 ◽

1978 ◽

pp. 73-80 ◽

Cited By ~ 3

Author(s):

T. S. Herman ◽

S. E. Jones

Keyword(s):

Complete Remission ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

Journal of Clinical Oncology ◽

10.1200/jco.1994.12.12.2543 ◽

1994 ◽

Vol 12 (12) ◽

pp. 2543-2551 ◽

Cited By ~ 133

Author(s):

C Haioun ◽

E Lepage ◽

C Gisselbrecht ◽

B Coiffier ◽

A Bosly ◽

...

Keyword(s):

Complete Remission ◽

Confidence Interval ◽

Hodgkin’S Lymphoma ◽

Autologous Bone Marrow Transplantation ◽

Autologous Bone Marrow ◽

Hodgkin's Lymphoma ◽

Induction Treatment ◽

Sequential Chemotherapy ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

PURPOSE Intensive chemotherapy followed by autotransplantation has given promising results in partially responding or sensitive relapsed patients with aggressive non-Hodgkin's lymphoma. In 1987, we designed a randomized study to evaluate the potential benefit of a high-dose regimen containing cyclophosphamide, carmustine, and etoposide (CBV) followed by autotransplantation over a consolidative sequential chemotherapy (ifosfamide, etoposide, asparaginase, and cytarabine) in patients in first complete remission with intermediate- and high-grade non-Hodgkin's lymphoma. PATIENTS AND METHODS Patients were younger than 55 years and had at least one adverse prognostic factor. Induction treatment was that of the LNH84 protocol with an open randomization on the anthracycline. Patients in complete remission were further randomly assigned to receive either consolidation procedure. RESULTS After induction treatment, 464 patients were assessable for the consolidation phase. With a median follow-up duration of 28 months, the 3-year disease-free survival rate was 52% (95% confidence interval, 45% to 59%) in the sequential chemotherapy arm and 59% (95% confidence interval, 52% to 66%) in the autologous transplant arm (P = .46, relative risk = 0.90). The 3-year survival rate did not differ between sequential chemotherapy and autotransplantation, at 71% (95% confidence interval, 64% to 78%) and 69% (95% confidence interval, 62% to 76%), respectively (P = .60, relative risk = 1.11). CONCLUSION For such a subset of patients, consolidation with the CBV regimen followed by autologous bone marrow transplantation is not superior to sequential chemotherapy.

Download Full-text